Martyna Lewand: Major Immunology Deal Brings FB102 to argenx
Martyna Lewand, Editor-in-Chief at BioBriefs.com, shared a post on LinkedIn։
”From today’s BioBriefs.com – You should subscribe, it’s free:
Immunology M and A accelerates pipeline
argenx agreed to buy Forte Biosciences for $2.2 billion in cash, valuing Forte at 77 dollar per share and marking a continuation of deal momentum across mid-cap immunology. The acquisition is designed to bring Forte’s phase 2-stage anti-CD122 antibody FB102 into argenx’s antibody pipeline, following earlier clinical validation in vitiligo.
Forte’s FB102 showed a 29.6% improvement in facial vitiligo in a recent phase 1b study, and argenx expects later this year readouts in celiac disease. The companies position FB102 as a potential ‘pipeline-in-a-product’ opportunity that could expand into other autoimmune diseases.
The buyout also ends Forte’s independent development after pressure from shareholders in 2022, when Forte’s atopic dermatitis program failed in phase 2 and the company faced calls to liquidate. argenx’s commercial and late-stage development capabilities are intended to extend FB102’s clinical path.
Key takeaway: argenx’s acquisition targets a mechanism aimed at T-cell and NK-cell activity, aiming to broaden antibody competition in autoimmune care with an asset now moving through late early-stage development.”
Stay updated with Hemostasis Today.
-
Nov 17, 2026, 01:27X. Long Zheng: Optimizing Treatment in Immune TTP
-
Nov 16, 2026, 15:35Jim Hoffman: Could Blood Purification Change the Fight Against Cancer?
-
Nov 16, 2026, 15:16How Do Artificial Hearts Affect Platelet Function? – Platelets Journal
-
Nov 16, 2026, 15:10Assessing Coagulation Activation in DOAC – Treated Patients – JTH
-
Nov 16, 2026, 15:00Davide Antonio Mei: Should Anticoagulation Continue After AF Ablation?
-
Nov 16, 2026, 14:55Danielle Boyle: Beyond Platelet Counts – Why Patient Stories Matter
-
Nov 16, 2026, 14:28Jan Sloves: The Future of Vascular Ultrasound
-
Nov 16, 2026, 13:49Bahman Rasouli: A Rare Vascular Manifestation of Recurrent Papillary Thyroid Carcinoma
-
Nov 16, 2026, 13:28Muhammad Danyal: Platelet Patterns in Hepatitis B and C